Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

PURPOSE: The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer (AGC). However, as demonstrated in HER2-negative AGC, oxaliplatin-based regimens could improve tolerance remaining effective. The aim of this t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Chemother Pharmacol
Main Authors: Rivera, Fernando, Romero, C., Jimenez-Fonseca, P., Izquierdo-Manuel, M., Salud, A., Martínez, E., Jorge, M., Arrazubi, V., Méndez, J. C., García-Alfonso, P., Reboredo, M., Barriuso, J., Muñoz-Unceta, N., Jimeno, R., López, C.
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2019
Teme:
Clinical Trial Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6779679/
https://ncbi.nlm.nih.gov/pubmed/30927036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03820-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki